In an ECOSPOR III analysis, all-cause hospitalization by week 4 fell to 3.4% with fecal microbiota spores vs 16.1% with placebo in recurrent C difficile infection.
|Articles|November 3, 2021
C Diff Foundation Hosts Its Annual Conference
Author(s)Contagion Editorial Team
The organization is hosting its 9th Annual International C Diff Conference and Health EXPO on Thursday and Friday this week. The conference is virtual and free to the public.
Advertisement
The C Diff Foundation is hosting its 9th Annual International C Diff Conference and Health EXPO this Thursday and Friday. There will be over 40 international topic-experts dedicated in disciplines of healthcare, pharma, biotech, and academia.
Presenters will deliver data and discuss critical information on Clostridioides difficile in live online presentations. There will be on-demand poster presentations, exhibitors, and real-time networking opportunities available.
“The annual C Diff Foundation conference is a highlight of my learning year. The combination of academia, pharmaceutical, and governmental representation creates a learning environment that is second to none,"Paul Feuerstadt, MD, FACG, AGAF, stated. "I went initially in 2014 and have circled the conference dates on my calendar annually as immobile. The timing during C. difficile awareness month is tremendous as it summarizes all of the newest findings throughout the year.”
The conference is virtual and registration is complimentary this year.
To learn more about the conference, guest speakers, and the diverse topics being presented visit
Advertisement
Related to this article
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Labcorp data presented at IDWeek 2026 show measles PCR testing nearly quadrupled and positivity rose sharply from April 2025 through March 2026, as clinicians shift toward guideline-recommended molecular testing amid ongoing US outbreaks.
In this first IDWeek 2026 roundup, oral olorofim matched AmBisome in invasive aspergillosis, aztreonam-avibactam held activity as MBL-producing CRE rose, pritelivir cut hospitalizations in refractory HSV, and zelicapavir shortened RSV symptoms in high-risk adults.
David Altarac, MD, discusses the 2026 IDSA guidance, which prioritizes sulbactam-durlobactam plus a carbapenem for invasive carbapenem-resistant Acinetobacter infections.
Investigational agent Zelicapavir cut time to complete RSV symptom resolution by up to a week and lowered hospitalization in high-risk adults.
Preliminary SABEDTIO data from IDWeek 2026 show early dual IV therapy cut prolonged S aureus bacteremia to 6% from 16%, with safe oral transition at 72 hours.
Alejandra Gurtman, MD, discussed the phase 2 data at IDWeek 2026 which showed the investigational 25-valent pneumococcal conjugate vaccine 25vPnC produced serotype 3 antibody levels about 15-fold higher than Prevnar 20 after the booster dose, targeting a serotype still behind 10.6% of invasive pneumococcal disease in US children younger than five years.
Advertisement
Advertisement
Trending on Contagion Live
1
A Closer Look at IDSA/ESCMID 2026 Consensus Statements 6 and 7 on Staphylococcus aureus Bacteremia
2
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
3
Thinking Outside the IV: Implementation of a COpAT Program for Patients With Bone and Joint Infections
4
Early Dual Therapy Shortens Staphylococcus aureus Bacteremia in SABEDTIO Trial
5